India Exchange Filings

Gujarat Themis Biosyn Q2 and H1 FY27 Investor Presentation

Gujarat Themis Biosyn Ltd reports Q2 FY27 standalone revenue of ₹47.5 crore, up 12.1% YoY, and consolidated net loss of ₹13.8 crore

  • Standalone Q2 EBITDA was ₹17.7 crore (37.4% margin); net profit fell 40.6% YoY to ₹8.5 crore.
  • H1 FY27 standalone revenue rose 16.7% to ₹91.2 crore; EBITDA margin was 42.2% and net profit was ₹19.5 crore, down 16.3%.
  • Consolidated Q2 EBITDA loss was ₹0.9 crore; results included ₹15.57 crore in unrealized FX translation losses and ₹1.2 crore in earthquake-related exceptional expenses at MicroBiopharm Japan, with 13 days of post-acquisition consolidation.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.